The rollercoaster ride stopps and danish IO Biotech goes bust

End of the road for IO Biotech after FDA setback and funding squeeze. At the centre of its strategy was Cylembio (IO102-IO103), a therapeutic vaccine targeting immune-suppressive mechanisms in cancer. However, the candidate narrowly missed its primary endpoint in a Phase III trial in advanced melanoma, failing to demonstrate statistical superiority over Keytruda. The outcome dealt a critical blow to the company’s prospects.

The situation worsened in September 2025, when the U.S. Food and Drug Administration advised against filing for approval based on the available data. Without a viable regulatory pathway and facing the prospect of an additional, costly confirmatory trial, IO Biotech’s options quickly narrowed.

Looking for new strategies amid financial headwinds

Financially, the company had raised a respectable—though not exceptional—amount of capital. A Series B round in early 2021 brought in approximately $127m, followed by a US IPO later that year raising around $115m, with investors including HBM Healthcare Investments and Kurma Partners. A subsequent financing agreement with the European Investment Bank provided access to up to €57.5m. In total, IO Biotech secured roughly $170–180m in major funding.

Yet this proved insufficient to weather clinical failure. By the end of 2025, the company’s cash reserves had dwindled to around $30m—barely enough to sustain operations into early 2026. Efforts to secure additional funding or strategic partnerships following the trial readout were unsuccessful.

Cost-cutting measures, including the dismissal of around half the workforce in late 2025, failed to stabilise the situation. By early 2026, the company had initiated a review of strategic alternatives. Following the FDA’s stance, however, investor appetite evaporated.

No way out

IO Biotech has now entered bankruptcy proceedings. A court-appointed trustee will oversee the liquidation of assets, including intellectual property and clinical data. All employees and executives have been dismissed, and the board has resigned in full. Shareholders are unlikely to see any recovery, with the stock having lost more than 95% of its value over the past year.

The collapse underscores a familiar dynamic in biotech: even well-financed companies can falter when late-stage clinical data disappoint. In IO Biotech’s case, the failure was less about access to capital than the inability to translate scientific promise into regulatory success — leaving too little runway to recover once the pivotal trial fell short.